Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DDRGK domain-containing protein 1 (**DDRGK1**) is a key component of the UFM1 conjugation (ufmylation) system, acting both as a scaffold and a reader for UFM1-modified proteins at the endoplasmic reticulum (ER)[3]. Its PCI domain mediates protein interactions, while an N-terminal signal peptide anchors it to the ER membrane[1][2][3]. DDRGK1 regulates lysosomal function and autophagy, controls the unfolded protein response, and is essential for the proper recycling of ribosomes from the ER. It further modulates NF-κB signaling and affects apoptosis in ER-stressed secretory tissues[3][4]. Loss or dysfunction of DDRGK1 has been implicated in hematopoietic disorders, impaired plasma cell differentiation, specific genetic dysplasias, and intestinal inflammation. Direct pharmacological targeting of DDRGK1 is not established, but its central role in cellular stress responses and immunity highlights its potential as a future therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DDRGK domain-containing protein 1 (DDRGK1).